State Street Corp Chinook Therapeutics, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $4.09 Million - $8.46 Million	219,269 Added 8.16%	2,907,317 $112 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $626,350 - $779,665	29,092 Added 1.09%	2,688,048 $62.2 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $3.6 Million - $5.29 Million	193,237 Added 7.84%	2,658,956 $69.7 Million
Q3 2022 Nov 15, 2022	BUY	$17.51 - $23.37 $16 Million - $21.3 Million	912,778 Added 58.78%	2,465,719 $48.5 Million
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $554,727 - $828,346	-44,061 Reduced 2.76%	1,552,941 $27.2 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $3.72 Million - $5.16 Million	309,362 Added 24.03%	1,597,002 $26.1 Million
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $1.18 Million - $1.86 Million	-110,529 Reduced 7.91%	1,287,640 $21 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $5.27 Million - $6.81 Million	458,063 Added 48.72%	1,398,169 $17.8 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $9.18 Million - $12.8 Million	675,206 Added 254.89%	940,106 $13.3 Million
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $305,462 - $411,954	-21,557 Reduced 7.53%	264,900 $4.12 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $3.41 Million - $5.99 Million	286,457 New	286,457 $4.54 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.